Trial Profile
A Randomized, Open Label, Multi-center, Comparative Trial, to Assess the Efficacy and Safety of Pritelivir for the Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects (PRIOH-1)
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 14 Jan 2024
Price :
$35
*
At a glance
- Drugs Pritelivir (Primary) ; Cidofovir; Cidofovir; Foscarnet; Imiquimod; Imiquimod
- Indications Herpes simplex virus infections
- Focus Registrational; Therapeutic Use
- Acronyms PRIOH-1
- Sponsors AiCuris
- 01 Dec 2023 Imiquimod (Topical and IV solution) and Cidofovir topical and IV are added to the active comparators arm.
- 01 Dec 2023 Planned End Date changed from 1 Oct 2024 to 1 Apr 2025.
- 01 Dec 2023 Planned primary completion date changed from 1 Jun 2024 to 1 Jan 2025.